Amy Li, an analyst from Jefferies, has initiated a new Buy rating on Liquidia Technologies (LQDA).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amy Li’s rating is based on several compelling factors that suggest potential growth for Liquidia Technologies. Firstly, the company’s lead product, Yutrepia, has shown a promising start with a solid early launch, capturing a significant number of patients and prescriptions. This success is bolstered by the expectation that Yutrepia will exceed revenue forecasts by a substantial margin, potentially reaching $108 million by the fiscal year 2025, which is significantly higher than the consensus estimate.
Furthermore, despite ongoing patent litigation and competition from other products, Yutrepia’s unique advantages, such as faster titration to therapeutic doses without increasing cough risk, position it well in the market, particularly for patients with pulmonary hypertension and interstitial lung disease. The positive feedback from key opinion leaders and the encouraging clinical data further support the potential for continued uptake and market differentiation. These factors contribute to the belief that Liquidia Technologies is poised for profitability by the end of 2025, justifying the Buy rating with a price target of $43.
According to TipRanks, Li is an analyst with an average return of -71.7% and a 0.00% success rate.
In another report released on August 13, BTIG also maintained a Buy rating on the stock with a $49.00 price target.